|
26 Jun 2023 |
Portage Biotech Announces First Patient Dosed in Phase 1a Trial of PORT-6 in Select Solid Tumors
|
|
26 Jun 2023 |
Pfizer Provides Update on GLP-1-RA Clinical Development Program for Adults with Obesity and Type 2 Diabetes Mellitus
|
|
24 Jun 2023 |
Sun Pharma Presents Data from First-in-Human Phase 1 Studies of GL0034 at the American Diabetes Association 83rd Scientific Sessions
|
|
24 Jun 2023 |
Inversago Pharma Presents Data from Phase 1b Trial of INV-202, a Peripheral CB1r Blocker for Metabolic Syndrome, at the 83rd American Diabetes Association Scientific Sessions
|
|
24 Jun 2023 |
FDA Approves Pfizer’s LITFULO™ (Ritlecitinib) for Adults and Adolescents With Severe Alopecia Areata
|
|
24 Jun 2023 |
Lilly's phase 2 results published in the New England Journal of Medicine show orforglipron, a once-daily oral nonpeptide GLP-1 receptor agonist, achieved up to 14.7% mean weight reduction at 36 weeks in adults with obesity or overweight
|
|
24 Jun 2023 |
Lexicon Announces Planned Advancement of LX9211 Into Late-Stage Development
|
|
23 Jun 2023 |
Tvardi Therapeutics Announces First Patients Dosed in its Phase 2 Liver Cancer Trial Using TTI-101, a Novel STAT3 Inhibitor
|
|
23 Jun 2023 |
SELLAS Announces First Patient Dosed in Phase 2a Clinical Trial of GFH009 in Acute Myeloid Leukemia
|
|
22 Jun 2023 |
AceLink Therapeutics Receives FDA Clearance to Initiate a Phase 2 Study of AL1211 in Patients with Fabry Disease
|
|
21 Jun 2023 |
U.S. FDA Approves First Anti-Inflammatory Drug for Cardiovascular Disease
|
|
21 Jun 2023 |
Accutar Biotechnology Announces First Patient Dosed with AC0676 in Phase 1 Study in Patients with Relapsed/Refractory B-cell Malignancies
|
|
21 Jun 2023 |
Escient Pharmaceuticals Announces Positive Results from Phase 1 Study of EP262, a First-in-Class Oral MRGPRX2 Antagonist for Mast Cell Mediated Disorders
|
|
21 Jun 2023 |
Enanta Pharmaceuticals Announces Positive Data From a Phase 1 Clinical Study of EDP-323, an Oral, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus
|
|
21 Jun 2023 |
Geron Announces Submission of New Drug Application to FDA for First-in-Class Telomerase Inhibitor Imetelstat
|
|
21 Jun 2023 |
Pfizer’s TALZENNA® in Combination with XTANDI® Receives U.S. FDA Approval
|
|
19 Jun 2023 |
Allgenesis Announces Encouraging Phase 1b Data Showing AG-80308 Providing Improvements in Multiple Signs and Symptoms in Dry Eye Patients
|
|
18 Jun 2023 |
Chinook Therapeutics Presents Data from CHK-336 Phase 1 Trial in Healthy Volunteers and New Insights into the Role of Failed Repair in Chronic Kidney Disease at the 60th European Renal Association (ERA) Congress
|
|
18 Jun 2023 |
Sling Therapeutics Presents Data Demonstrating Linsitinib Prevents Thyroid Eye Disease Progression in a Mouse Model at ENDO 2023
|
|
16 Jun 2023 |
UPDATE: Lexicon Announces FDA Approval of INPEFA™ (sotagliflozin) for Treatment of Heart Failure
|
|
15 Jun 2023 |
Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS
|
|
15 Jun 2023 |
Nurix Therapeutics Presents Data from Studies of Its Targeted Protein Degraders in B Cell Malignancies and Initiates Expansion of NX-2127 Phase 1b Trial in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma Indications
|
|
15 Jun 2023 |
Ventyx Biosciences Announces Initiation of Dosing in a Phase 1 Trial of VTX3232, a Novel CNS-Penetrant NLRP3 Inhibitor
|
|
15 Jun 2023 |
Mithra Announces New Positive Preclinical Data from CSF-1R Inhibitor Program
|
|
15 Jun 2023 |
MindRank Announces First-in-Human Phase 1 Study of MDR-001 in China
|
